
  
    
      
        Background_NNP
        Numerous_JJ diseases_NNS require_VBP treatment_NN by_IN systemic_JJ delivery_NN
        of_IN a_DT therapeutic_JJ protein_NN ._. Repetitive_NNP or_CC continuous_JJ
        injections_NNS are_VBP the_DT only_JJ delivery_NN method_NN used_VBN in_IN daily_JJ
        practice_NN ._. As_IN a_DT mean_NN of_IN reducing_VBG the_DT inconvenience_NN of_IN
        multiple_JJ injections_NNS or_CC implantation_NN of_IN mini_NN pumps_NNS ,_, gene_NN
        transfer_NN technology_NN may_MD offer_VB certain_JJ advantages_NNS ._. In_IN order_NN
        to_TO achieve_VB a_DT high_JJ plasma_NN concentration_NN ,_, whatever_WDT the_DT vector_NN
        used_VBD ,_, the_DT transfection_NN of_IN a_DT large_JJ tissue_NN mass_NN is_VBZ required_VBN
        (_( e_SYM ._. g_SYM ._. liver_NN or_CC muscle_NN )_) ._. In_IN rodents_NNS ,_, intravenous_JJ injection_NN
        of_IN a_DT non-targeted_JJ vector_NN -_: viruses_NNS or_CC plasmid_NN preparations_NNS
        -_: induces_VBZ mainly_RB transfection_NN in_IN the_DT liver_NN and_CC the_DT spleen_NN [_NN
        1_CD 2_CD ]_NN ._. As_IN of_IN today_NN ,_, transfection_NN of_IN other_JJ large_JJ organs_NNS by_IN
        viral_JJ vectors_NNS has_VBZ not_RB been_VBN accomplished_VBN in_IN by_IN way_NN of_IN
        systemic_JJ delivery_NN [_NN 3_CD ]_NN ._. The_DT main_JJ inconveniences_NNS of_IN
        intravenous_JJ administration_NN of_IN first_JJ generation_NN adenoviral_NN
        vectors_NNS are_VBP their_PRP$ immunogenicity_NN [_NN 4_CD ]_NN and_CC hepatic_JJ toxicity_NN
        [_NN 5_CD 6_CD ]_NN ._. The_DT muscle_NN as_IN a_DT large_JJ tissue_NN mass_NN is_VBZ a_DT candidate_NN
        for_IN production_NN of_IN recombinant_JJ protein_NN ,_, but_CC the_DT transfection_NN
        is_VBZ limited_VBN to_TO the_DT injection_NN site_NN ._. Intra_NNP muscular_JJ
        administration_NN is_VBZ an_DT attractive_JJ option_NN as_IN it_PRP avoids_VBZ liver_NN
        damage_NN ,_, but_CC the_DT levels_NNS reached_VBN are_VBP not_RB satisfactory_JJ [_NN 7_CD ]_NN ._.
        An_DT alternative_NN to_TO transfection_NN with_IN adenoviral_NN vector_NN is_VBZ
        the_DT injection_NN of_IN naked_JJ DNA_NNP into_IN the_DT muscle_NN followed_VBN by_IN
        electroporation_NN ._. The_DT electroporation_NN setting_VBG that_WDT induced_VBD
        high_JJ blood_NN levels_NNS of_IN excreted_JJ encoded_JJ proteins_NNS were_VBD defined_VBN
        by_IN Bettan_NNP et_CC al_NN ._. [_NN 8_CD ]_NN and_CC Mir_NNP et_CC al_NN ._. [_NN 9_CD 10_CD ]_NN ._. This_DT
        setting_NN of_IN 8_CD pulses_NNS of_IN 20_CD ms_NNS and_CC 200_CD V_NNP /_NN cm_NN at_IN a_DT frequency_NN of_IN
        1_CD Hz_NNP increased_VBD the_DT plasmid_NN expression_NN up_IN to_TO 2_CD logs_NNS in_IN the_DT
        C_NNP 57_CD Bl_NNP /_NN 6_CD mice_NNS ._. In_IN this_DT study_NN ,_, first_JJ generation_NN adenovirus_JJ
        transfection_NN and_CC plasmid_NN electroporation_NN of_IN the_DT muscle_NN were_VBD
        compared_VBN to_TO determine_VB which_WDT one_CD is_VBZ the_DT most_RBS suitable_JJ for_IN
        obtaining_VBG high_JJ plasma_NN levels_NNS of_IN two_CD proteins_NNS of_IN interest_NN ,_,
        namely_RB :_: mhATF-BPTI_JJ and_CC endostatin_NN ._. mhATF-BPTI_JJ is_VBZ a_DT newly_RB
        designed_VBN chimeric_JJ protein_NN that_WDT has_VBZ angiostatic_JJ properties_NNS
        and_CC endostatin_NN is_VBZ an_DT angiostatic_JJ undergoing_VBG clinical_JJ trials_NNS
        that_WDT was_VBD used_VBN for_IN comparison_NN ._. As_IN these_DT two_CD proteins_NNS are_VBP
        interfering_VBG with_IN tissue_NN healing_NN ,_, the_DT luciferase_NN gene_NN was_VBD
        used_VBN to_TO study_VB the_DT local_JJ tissue_NN damage_NN caused_VBN by_IN the_DT two_CD
        transfection_NN methods_NNS ._.
        Another_DT application_NN of_IN electroporation_NN is_VBZ the_DT
        transfection_NN of_IN tumours_NNS ._. Human_NNP as_RB well_RB as_IN rodent_NN tumours_NNS
        vary_VBP greatly_RB in_IN expressing_VBG the_DT surface_NN receptors_NNS for_IN
        adenovirus_JJ ._. Consequently_RB ,_, the_DT gene_NN transfer_NN with_IN adenoviral_NN
        vectors_NNS is_VBZ very_RB low_JJ in_IN tumours_NNS that_WDT poorly_RB express_VB those_DT
        receptors_NNS ._. Plasmid_NNP DNA_NNP alone_RB is_VBZ not_RB very_RB efficient_JJ
        transfectant_NN ,_, therefore_RB the_DT electroporation_NN offers_VBZ a_DT
        possibility_NN to_TO transfect_NN tumours_NNS resistant_JJ to_TO viral_JJ
        infection_NN [_NN 11_CD 12_CD ]_NN ._. In_IN this_DT study_NN ,_, the_DT electroporation_NN of_IN
        a_DT non-permissive_JJ adenocarcinoma_NN of_IN the_DT lung_NN is_VBZ compared_VBN to_TO
        the_DT adenoviral_NN vector_NN ._.
      
      
        Results_NNS
        
          Electroporation_NNP enhances_VBZ plasmid_NN gene_NN expression_NN in_IN
          muscle_NN
          The_DT luciferase_NN activity_NN in_IN C_NNP 57_CD Bl_NNP /_NN 6_CD mice_NNS muscle_NN was_VBD
          compared_VBN when_WRB transfected_JJ with_IN plasmid_NN alone_RB or_CC with_IN
          plasmid_NN followed_VBN by_IN electroporation_NN at_IN various_JJ voltage_NN ._.
          As_IN depicted_VBN on_IN Fig_NNP 1_CD electroporation_NN increased_VBD
          transfection_NN to_TO a_DT maximum_NN of_IN 2_CD logs_NNS which_WDT was_VBD attained_VBN at_IN
          180_CD V_NNP /_NN cm_NN ._. There_EX was_VBD no_DT more_JJR enhancing_VBG effect_NN when_WRB the_DT
          voltage_NN was_VBD lowered_VBN to_TO 100_CD V_NNP /_NN cm_NN ._. It_PRP remained_VBD to_TO be_VB
          determined_VBN if_IN the_DT 2_CD log_NN increase_NN in_IN transgene_NN expression_NN
          was_VBD enough_RB to_TO obtain_VB high_JJ blood_NN levels_NNS of_IN a_DT secreted_JJ
          transgenic_JJ protein_NN ._. Therefore_RB ,_, plasmids_NNS encoding_VBG
          mhATF-BPTI_JJ or_CC human_JJ endostatin_NN were_VBD injected_VBN into_IN the_DT
          muscle_NN with_IN and_CC without_IN electroporation_NN and_CC the_DT plasma_NN
          level_NN of_IN the_DT encoded_JJ protein_NN was_VBD monitored_VBN ._. To_TO verify_VB
          that_IN the_DT injection_NN had_VBD been_VBN properly_RB performed_VBN ,_, an_DT equal_JJ
          amount_NN of_IN pAdapt_NN Luc_NNP was_VBD added_VBN to_TO the_DT plasmid_NN preparation_NN
          and_CC the_DT mixture_NN was_VBD injected_VBN in_IN a_DT separate_JJ group_NN of_IN
          animals_NNS ._. Both_DT groups_NNS (_( with_IN and_CC without_IN pLuc_NN )_) ,_, showing_VBG
          similar_JJ expression_NN levels_NNS of_IN the_DT secreted_JJ encoded_JJ protein_NN
          were_VBD pooled_VBN ._. As_IN shown_VBN in_IN Fig_NNP 2_CD the_DT injection_NN of_IN plasmid_NN
          alone_RB -_: pATF-BPTI_JJ or_CC pEndostatin_NN -_: did_VBD not_RB lead_VB to_TO blood_NN
          levels_NNS above_IN the_DT background_NN ._. In_IN contrast_NN ,_, plasmid_NN
          injection_NN followed_VBN by_IN electroporation_NN resulted_VBD in_IN
          detectable_JJ blood_NN levels_NNS of_IN mhATF-BPTI_JJ (_( 5_CD ng_NN /_NN ml_NN )_) and_CC of_IN
          hEndostatin_NN (_( 25_CD ng_NN /_NN ml_NN )_) ._. These_DT concentrations_NNS are_VBP
          however_RB ,_, far_RB below_IN what_WP one_PRP can_MD achieve_VB with_IN low_JJ dose_NN
          adenovirus_JJ (_( 10_CD 9_CD iu_NN )_) injected_VBN intravenously_RB which_WDT results_NNS
          in_IN protein_NN production_NN by_IN the_DT liver_NN ._.
        
        
          Plasmid_NNP electroporation_NN does_VBZ not_RB compete_VB with_IN
          adenoviral_NN vectors_NNS
          The_DT volume_NN of_IN injection_NN limits_VBZ the_DT quantity_NN of_IN
          adenovirus_JJ or_CC plasmid_NN that_WDT can_MD be_VB injected_VBN into_IN the_DT
          gastrocnemius_JJ of_IN a_DT mouse_NN without_IN overflow_NN ._. The_DT maximal_NN
          volume_NN of_IN 50_CD μL_NN and_CC the_DT highest_JJS concentrations_NNS of_IN the_DT
          available_JJ batches_NNS of_IN either_DT recombinant_JJ adenovirus_JJ (_( 10_CD
          10_CD iu_NN /_NN 50_CD μl_NN )_) or_CC plasmid_NN (_( 50_CD μg_NN /_NN 50_CD μl_NN )_) were_VBD employed_VBN to_TO
          compare_VB the_DT two_CD gene_NN transfer_NN methods_NNS ._. The_DT following_VBG
          electroporation_NN conditions_NNS i_NNP ._. e_SYM ._. 200_CD V_NNP /_NN cm_NN ,_, 8_CD pulses_NNS of_IN 20_CD
          ms_NNS at_IN a_DT frequency_NN of_IN 1_CD Hz_NNP ,_, were_VBD employed_VBN ._. The_DT luciferase_NN
          activity_NN was_VBD measured_VBN in_IN the_DT gastrocnemius_JJ muscle_NN of_IN
          C_NNP 57_CD BL_NNP /_NN 6_CD mice_NNS 2_CD days_NNS after_IN the_DT gene_NN delivery_NN ._. As_IN depicted_VBN
          on_IN figure_NN 3_CD transgene_NN expression_NN was_VBD roughly_RB the_DT same_JJ with_IN
          adenoviral_NN vector_NN as_IN with_IN plasmid_NN electroporation_NN ._. The_DT
          leakage_NN of_IN adenovirus_JJ out_IN of_IN the_DT muscle_NN induces_VBZ a_DT
          significant_JJ luciferase_NN activity_NN in_IN the_DT liver_NN and_CC in_IN the_DT
          spleen_NN ._. This_DT level_NN corresponds_NNS to_TO an_DT intravenous_JJ virus_NN
          dose_NN that_WDT is_VBZ far_RB below_IN that_DT found_VBD to_TO be_VB toxic_JJ for_IN the_DT
          liver_NN ._. In_IN contrast_NN ,_, the_DT electroporation_NN of_IN the_DT muscle_NN was_VBD
          not_RB accompanied_VBN by_IN any_DT transgene_NN expression_NN in_IN the_DT liver_NN
          but_CC a_DT few_JJ mice_NNS showed_VBD a_DT very_RB low_JJ luciferase_NN activity_NN in_IN
          the_DT spleen_NN ._. It_PRP is_VBZ noteworthy_JJ that_IN the_DT background_NN of_IN
          luciferase_NN is_VBZ higher_JJR in_IN the_DT muscle_NN than_IN in_IN the_DT liver_NN ._.
          This_DT was_VBD always_RB observed_VBN and_CC considered_VBN to_TO be_VB inherent_JJ to_TO
          the_DT detection_NN method_NN ._. To_TO further_VB investigate_VB the_DT
          secretion_NN capacity_NN of_IN the_DT muscle_NN ,_, 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP mhAB_NN
          were_VBD injected_VBN in_IN the_DT gastrocnemius_JJ of_IN mice_NNS ._. The_DT plasma_NN
          levels_NNS of_IN mhAB_NN ,_, monitored_VBN for_IN 3_CD weeks_NNS after_IN the_DT
          injection_NN ,_, showed_VBD a_DT peak_NN at_IN 10_CD ±_NN 4_CD ng_NN /_NN ml_NN on_IN day_NN 10_CD after_IN
          administration_NN ._. In_IN view_NN of_IN the_DT variation_NN ,_, transduction_NN of_IN
          the_DT muscle_NN with_IN first_JJ generation_NN Ad_NN 5_CD is_VBZ not_RB
          significantly_RB more_RBR efficient_JJ that_IN with_IN
          electroporation_NN ._.
        
        
          Local_JJ injury_NN caused_VBN by_IN muscle_NN
          electroporation_NN
          The_DT damage_NN induced_VBN by_IN the_DT electroporation_NN was_VBD assessed_VBN
          by_IN clinical_JJ observation_NN ,_, histological_JJ examination_NN of_IN
          muscle_NN sections_NNS ,_, and_CC determination_NN of_IN creatine_NN kinase_NN in_IN
          the_DT plasma_NN ._. Clinical_NNP symptoms_NNS were_VBD not_RB observed_VBN in_IN any_DT of_IN
          the_DT mice_NNS during_IN the_DT observation_NN period_NN of_IN 2_CD weeks_NNS ._. At_IN
          autopsy_NN ,_, practiced_VBD 2_CD ,_, 7_CD and_CC 14_CD days_NNS after_IN the_DT
          electroporation_NN ,_, macroscopic_JJ examination_NN of_IN the_DT treated_VBN
          areas_NNS showed_VBD local_JJ abnormalities_NNS and_CC an_DT oedema_NN of_IN the_DT
          whole_JJ gastrocnemius_JJ muscle_NN ._. On_IN day_NN 2_CD the_DT muscles_NNS were_VBD
          just_RB a_DT bit_NN pale_JJ whereas_IN at_IN day_NN 7_CD and_CC 14_CD the_DT site_NN of_IN
          electroporation_NN was_VBD white_JJ /_NN creamy_JJ and_CC felt_VBD hard_RB upon_IN
          palpation_NN (_( fig_NN 4_LS )_) ._. Microscopic_NNP examination_NN revealed_VBD
          severe_JJ muscle_NN necrosis_NNS (_( fig_NN 5_LS )_) that_WDT was_VBD accompanied_VBN by_IN a_DT
          severe_JJ polynuclear_NN eosinophilic_JJ and_CC mast_NN cell_NN
          infiltration_NN ._. The_DT quantification_NN of_IN the_DT pathological_JJ
          changes_NNS was_VBD assessed_VBN by_IN determining_VBG the_DT percentage_NN of_IN
          necrotic_JJ fibers_NNS on_IN transversal_NN sections_NNS of_IN the_DT muscle_NN at_IN
          the_DT site_NN of_IN electroporation_NN as_RB well_RB as_IN by_IN measuring_VBG the_DT
          creatine_NN kinase_NN (_( CK_NNP )_) concentration_NN in_IN the_DT blood_NN ._.
          Histological_NNP scoring_VBG confirmed_VBN that_IN the_DT muscle_NN damage_NN was_VBD
          maximal_NN at_IN 7_CD days_NNS after_IN the_DT electroporation_NN (_( Fig_NNP 6_CD )_) ._.
          Since_IN the_DT creatine_NN kinase_NN levels_NNS are_VBP not_RB decreasing_VBG
          within_IN the_DT first_JJ week_NN after_IN electroporation_NN ,_, the_DT muscle_NN
          lesions_NNS must_MD have_VB continued_VBN over_IN several_JJ days_NNS ._. In_IN
          contrast_NN ,_, after_IN an_DT acute_JJ muscle_NN injury_NN like_IN an_DT ischemic_JJ
          infarction_NN ,_, the_DT peak_NN of_IN CK_NNP occurs_VBZ within_IN few_JJ hours_NNS ._. This_DT
          first_JJ peak_NN may_MD have_VB occurred_VBN after_IN the_DT electroporation_NN
          but_CC was_VBD not_RB monitored_VBN ._. Thus_RB the_DT elevation_NN of_IN the_DT CK_NNP
          between_IN day_NN 7_CD and_CC 14_CD ,_, probably_RB reflect_VB the_DT slow_JJ necrosis_NNS
          of_IN the_DT muscle_NN fiber_NN occurring_VBG during_IN the_DT first_JJ week_NN ._. More_RBR
          importantly_RB ,_, the_DT electric_JJ pulse_NN delivery_NN caused_VBN on_IN its_PRP$
          own_JJ a_DT severe_JJ rhabdomyolysis_NNS and_CC the_DT prior_JJ injection_NN of_IN
          saline_NN significantly_RB increased_VBD the_DT muscle_NN damage_NN ,_, but_CC the_DT
          addition_NN of_IN naked_JJ DNA_NNP did_VBD not_RB influence_VB the_DT muscle_NN
          injury_NN ._.
          Other_JJ investigators_NNS showed_VBD that_DT protein_NN expression_NN
          from_IN injected_VBN DNA_NNP was_VBD correlated_JJ with_IN the_DT voltage_NN
          intensity_NN up_IN to_TO 250_CD v_NN /_NN cm_NN ._. Thus_RB ,_, to_TO determine_VB a_DT
          therapeutic_JJ window_NN for_IN the_DT electroporation_NN procedure_NN ,_, the_DT
          voltage_NN intensity_NN was_VBD gradually_RB diminished_VBN and_CC the_DT
          corresponding_JJ muscle_NN damage_NN assessed_VBN as_RB previously_RB (_( Fig_NNP
          7_CD )_) ._. The_DT degree_NN of_IN necrosis_NNS was_VBD indeed_RB correlated_JJ with_IN the_DT
          voltage_NN intensity_NN and_CC decreased_VBD to_TO background_NN at_IN 50_CD -_: 100_CD V_NNP
          /_NN cm_NN ._. Unfortunately_RB the_DT luciferase_NN expression_NN levels_NNS
          decreased_VBD as_RB fast_RB as_IN the_DT muscle_NN damage_NN ,_, and_CC no_DT
          therapeutic_JJ window_NN could_MD be_VB found_VBN with_IN these_DT
          settings_NNS ._.
        
        
          Intra-tumoral_NNP electroporation_NN as_IN compared_VBN to_TO
          transfection_NN with_IN adenovirus_JJ
          The_DT permissiveness_NNS to_TO adenoviral_NN vectors_NNS of_IN rodent_NN as_RB
          well_RB as_IN of_IN human_JJ tumours_NNS varies_VBZ within_IN a_DT range_NN of_IN 3_CD logs_NNS ._.
          One_CD of_IN the_DT reasons_NNS is_VBZ that_IN viral_JJ vectors_NNS are_VBP dependant_NN on_IN
          membrane_NN receptors_NNS to_TO enter_VB the_DT cells_NNS ._. Adenoviral_NNP
          transfection_NN can_MD be_VB dramatically_RB impaired_VBN in_IN tumours_NNS that_WDT
          lack_NN the_DT appropriate_JJ receptors_NNS ._. Therefore_RB ,_, transfection_NN
          of_IN naked_JJ DNA_NNP using_VBG electroporation_NN might_MD offer_VB a_DT
          possibility_NN to_TO transfect_NN adenoviral-resistant_JJ tumours_NNS ._.
          The_DT L_NNP 44_CD bronchial_NN adenocarcinoma_NN was_VBD selected_VBN from_IN among_IN
          ten_CD rat_NN tumours_NNS of_IN different_JJ histological_JJ origin_NN ,_, as_IN
          being_VBG very_RB poorly_RB permissive_JJ to_TO adenovirus_JJ ._. The_DT standard_JJ
          plasmid_NN electroporation_NN was_VBD compared_VBN to_TO adenoviral_NN gene_NN
          delivery_NN in_IN subcutaneously_RB growing_VBG tumours_NNS ._. As_IN depicted_VBN
          on_IN fig_NN 8_CD the_DT electroporation_NN of_IN 50_CD μg_NN pAdapt_NN Luc_NNP and_CC the_DT
          injection_NN of_IN 5_CD ._. 10_CD 9_CD iu_NN Ad_NNP Adapt_NNP Luc_NNP induce_VB roughly_RB similar_JJ
          luciferase_NN expression_NN ._. However_RB ,_, a_DT non-negligible_JJ
          proportion_NN of_IN adenoviruses_NNS leaks_NNS out_IN of_IN the_DT tumour_NN and_CC
          reaches_VBZ the_DT liver_NN ._. Such_JJ leakage_NN is_VBZ 600_CD times_NNS higher_JJR with_IN
          intra_NN tumoral_NN delivery_NN than_IN after_IN intra-muscular_JJ
          injection_NN as_IN judged_VBN by_IN the_DT luciferase_NN activity_NN measured_VBN
          in_IN the_DT liver_NN ._. In_IN contrast_NN ,_, there_EX is_VBZ no_DT leakage_NN of_IN the_DT
          luciferase_NN activity_NN from_IN the_DT tumour_NN after_IN plasmid_NN
          electroporation_NN ._. In_IN order_NN to_TO assess_VB the_DT toxicity_NN
          associated_VBN with_IN the_DT viral_JJ leakage_NN to_TO the_DT liver_NN ,_, graded_JJ
          doses_NNS of_IN luciferase_NN and_CC empty_JJ vectors_NNS were_VBD injected_VBN iv_NN in_IN
          Brown_NNP Norway_NNP rats_NNS ._. The_DT intravenous_JJ route_NN was_VBD chosen_VBN on_IN
          basis_NN of_IN its_PRP$ consistent_JJ reproducibility_NN ._. The_DT luciferase_NN
          activity_NN in_IN the_DT liver_NN was_VBD measured_VBN and_CC pathological_JJ
          changes_NNS were_VBD scored_VBN in_IN liver_NN sections_NNS ._. To_TO avoid_VB
          interference_NN by_IN the_DT transgene_NN ,_, the_DT liver_NN damage_NN were_VBD
          determined_VBN in_IN animals_NNS injected_VBN with_IN an_DT empty_JJ vector_NN ._.
          Figure_NN 9_CD shows_VBZ that_IN the_DT leakage_NN associated_VBN with_IN the_DT
          intra-tumoral_JJ injection_NN of_IN 5_CD ._. 10_CD 9_CD iu_NN and_CC 10_CD 10_CD iu_NN is_VBZ in_IN the_DT
          range_NN of_IN vector_NN doses_NNS that_WDT induce_VB a_DT mild_JJ to_TO moderate_VB
          liver_NN damage_NN ._. In_IN an_DT attempt_NN to_TO assess_VB the_DT therapeutic_JJ
          window_NN of_IN the_DT adenoviral_NN vector_NN in_IN this_DT poorly_RB permissive_JJ
          tumour_NN ,_, the_DT number_NN of_IN transduced_JJ cells_NNS in_IN the_DT tumour_NN was_VBD
          determined_VBN by_IN injection_NN of_IN vectors_NNS encoding_VBG the_DT
          β-galactosidase_JJ gene_NN (_( Table_NNP 1_LS )_) ._. It_PRP is_VBZ assumed_VBN that_IN no_DT
          significant_JJ effect_NN is_VBZ expected_VBN from_IN a_DT therapeutic_JJ
          transgene_NN (_( e_SYM ._. g_SYM thymidin_NN kinase_NN ,_, mhATF-BPTI_JJ or_CC endostatin_NN )_)
          if_IN the_DT percentage_NN of_IN transduced_JJ tumour_NN tissue_NN is_VBZ below_IN
          5_CD %_NN ._. The_DT intra_NN tumoral_NN injection_NN of_IN 10_CD 10_CD iu_NN adenovirus_JJ
          resulted_VBD in_IN the_DT transduction_NN of_IN only_RB 1_CD -_: 2_CD %_NN of_IN the_DT tumour_NN
          cells_NNS ,_, mostly_RB limited_JJ around_IN the_DT needle_NN track_NN (_( Table_NNP 1_LS )_) ._.
          This_DT vector_NN dose_NN of_IN 10_CD 10_CD iu_NN is_VBZ already_RB toxic_JJ for_IN the_DT
          liver_NN (_( Fig_NNP ._. 9_CD )_) ._. Thus_RB the_DT margin_NN between_IN efficacy_NN and_CC
          toxicity_NN of_IN the_DT adenovirus_JJ in_IN non-permissive_JJ tumour_NN is_VBZ
          not_RB wide_JJ enough_RB for_IN therapeutic_JJ applications_NNS ._.
        
      
      
        Discussion_NNP
        Several_JJ investigators_NNS have_VBP used_VBN electroporation_NN
        procedures_NNS to_TO increase_VB the_DT gene_NN expression_NN of_IN naked_JJ DNA_NNP
        injected_VBD in_IN rodents_NNS muscles_NNS or_CC in_IN tumours_NNS [_NN 13_CD 14_CD ]_NN ._. There_EX
        are_VBP basically_RB two_CD types_NNS of_IN muscle_NN electroporation_NN
        protocols_NNS :_: (_( 1_LS )_) high_JJ voltage_NN /_NN short_JJ pulses_NNS and_CC (_( 2_LS )_) low_JJ
        voltage_NN /_NN long_JJ pulses_NNS ._. The_DT highest_JJS plasma_NN levels_NNS of_IN an_DT
        encoded_JJ protein_NN were_VBD obtained_VBN with_IN low_JJ voltage_NN (_( 200_CD V_NNP /_NN cm_NN )_)
        long_JJ pulses_NNS (_( 20_CD ms_NNS )_) and_CC 8_CD pulses_NNS at_IN a_DT frequency_NN of_IN 1_CD Hz_NNP ,_,
        i_NNP ._. e_SYM ._. the_DT blood_NN concentration_NN of_IN human_JJ secreted_JJ alkaline_NN
        phosphatase_NN reached_VBD values_NNS around_IN 2_CD μg_NN /_NN ml_NN [_NN 8_CD ]_NN ._. The_DT
        plasmid_NN preparations_NNS described_VBN by_IN others_NNS are_VBP most_JJS of_IN the_DT
        time_NN endotoxin_NN free_JJ and_CC the_DT transgene_NN is_VBZ under_IN a_DT CMV_NNP
        promoter_NN without_IN any_DT nuclear_JJ transport_NN signal_NN ._. Using_VBG these_DT
        settings_NNS and_CC the_DT BTX_NNP electroporation_NN device_NN ,_, the_DT transgene_NN
        expression_NN after_IN intra_NN muscular_JJ plasmid_NN injection_NN could_MD be_VB
        enhanced_VBN by_IN a_DT factor_NN 100_CD ._. This_DT led_VBN to_TO plasma_NN serum_NN levels_NNS
        of_IN endostatin_NN around_IN 10_CD -_: 50_CD ng_NN /_NN ml_NN ._. The_DT dose_NN of_IN plasmid_NN
        per_IN injected_VBN muscle_NN could_MD not_RB be_VB easily_RB increased_VBN for_IN
        technical_JJ reasons_NNS ._. Given_VBN the_DT maximal_NN achievable_JJ plasmid_NN
        concentration_NN ,_, the_DT injection_NN volume_NN would_MD have_VB become_VBN too_RB
        large_JJ for_IN the_DT muscle_NN ._. Bettan_NNP et_CC al_NN ._. have_VBP shown_VBN that_IN
        increasing_VBG the_DT dose_NN from_IN 30_CD μg_NN to_TO 300_CD μg_NN by_IN multiple_JJ
        injections_NNS resulted_VBD in_IN 7_CD to_TO 10_CD fold_VB higher_JJR plasma_NN levels_NNS ._.
        Thus_RB ,_, the_DT intra_NN muscular_JJ injection_NN of_IN naked_JJ DNA_NNP followed_VBN by_IN
        electroporation_NN is_VBZ considered_VBN by_IN some_DT as_IN a_DT means_NN to_TO obtain_VB
        therapeutic_JJ plasma_NN levels_NNS of_IN proteins_NNS ._. However_RB this_DT range_NN
        of_IN plasma_NN concentration_NN can_MD also_RB be_VB achieved_VBN by_IN
        intramuscular_NN or_CC systemic_JJ administration_NN of_IN first_JJ
        generation_NN Ad_NN 5_CD vectors_NNS ._. The_DT toxicity_NN of_IN these_DT vectors_NNS is_VBZ
        well_RB documented_VBN [_NN 6_CD 5_CD ]_NN ._. Systemic_NNP delivery_NN of_IN adenovirus_JJ
        vectors_NNS induces_VBZ mild_JJ liver_NN damage_NN at_IN low_JJ dose_NN (_( 10_CD 9_CD iu_NN in_IN
        mice_NNS )_) and_CC severe_JJ hepatitis_NN and_CC bone_NN marrow_NN necrosis_NNS at_IN high_JJ
        dose_NN (_( 10_CD 11_CD iu_NN in_IN a_DT mice_NNS )_) ._. Intramuscular_NNP injection_NN of_IN 10_CD
        10_CD iu_NN induces_VBZ moderate_JJ local_JJ inflammation_NN [_NN 15_CD ]_NN ._. However_RB ,_,
        the_DT local_JJ and_CC systemic_JJ toxicity_NN of_IN the_DT adenoviruses_NNS can_MD be_VB
        dramatically_RB reduced_VBN by_IN using_VBG gutless_JJ viruses_NNS [_NN 16_CD ]_NN ._.
        Notably_RB ,_, we_PRP observed_VBD severe_JJ muscle_NN damage_NN after_IN the_DT
        electric_JJ pulse_NN delivery_NN ,_, which_WDT was_VBD worsened_VBN by_IN the_DT pre_NN
        injection_NN of_IN saline_NN but_CC was_VBD not_RB influenced_VBN by_IN the_DT presence_NN
        of_IN plasmid_NN ._. Most_JJS authors_NNS dealing_VBG with_IN electroporation_NN gene_NN
        transfer_NN did_VBD not_RB investigate_VB the_DT toxicity_NN of_IN
        electroporation_NN ._. All_DT differences_NNS between_IN those_DT published_VBN
        protocols_NNS and_CC our_PRP$ parameters_NNS were_VBD tested_VBN to_TO verify_VB if_IN they_PRP
        were_VBD responsible_JJ for_IN the_DT toxicity_NN observed_VBD in_IN our_PRP$ hands_NNS ,_,
        but_CC that_DT was_VBD not_RB the_DT case_NN ._. Similar_JJ damage_NN occurred_VBD after_IN
        using_VBG a_DT simple_JJ anaesthesia_NN (_( hypnorm_NN )_) or_CC in_IN combination_NN with_IN
        muscle_NN relaxants_NNS during_IN electroporation_NN ._. Different_JJ
        positions_NNS of_IN the_DT leg_NN between_IN the_DT electrodes_NNS were_VBD tested_VBN
        with_IN no_DT influence_NN on_IN the_DT toxicity_NN ._. No_DT difference_NN in_IN muscle_NN
        damage_NN was_VBD observed_VBN between_IN male_JJ and_CC female_JJ mice_NNS ._. The_DT
        influence_NN of_IN the_DT type_NN of_IN electrodes-needle_JJ or_CC calliper_NN -_:
        was_VBD not_RB tested_VBN in_IN our_PRP$ experiments_NNS ._. However_RB ,_, there_EX are_VBP
        indications_NNS from_IN previous_JJ publications_NNS that_IN both_DT electrodes_NNS
        would_MD induce_VB similar_JJ muscle_NN damage_NN ._. Indeed_RB ,_, Gehl_NNP et_CC al_NN ._.
        established_VBN that_IN the_DT toxicity_NN of_IN electroporation_NN was_VBD
        correlated_JJ with_IN the_DT degree_NN of_IN cell_NN permeabilisation_NN [_NN 17_CD ]_NN
        and_CC that_IN these_DT was_VBD similar_JJ when_WRB using_VBG needles_NNS or_CC calliper_NN [_NN
        18_CD ]_NN ._. Thus_RB ,_, it_PRP may_MD be_VB assumed_VBN that_IN the_DT electrode_NN type_NN is_VBZ
        not_RB of_IN crucial_JJ influence_NN on_IN the_DT toxicity_NN induced_VBN by_IN the_DT
        electroporation_NN ._. Therefore_RB we_PRP conclude_VBP that_IN the_DT
        rhabdomyolysis_NNS developed_VBN in_IN those_DT mice_NNS was_VBD not_RB influenced_VBN
        by_IN other_JJ parameters_NNS than_IN the_DT electric_JJ pulse_NN settings_NNS and_CC
        the_DT pre-injection_JJ of_IN buffer_NN ._. Only_RB two_CD investigators_NNS have_VBP
        reported_VBN muscle_NN damage_NN after_IN plasmid_NN electroporation_NN ._.
        Mathiesen_NNP described_VBD muscle_NN necrosis_NNS after_IN plasmid_NN
        electroporation_NN that_WDT increased_VBD with_IN the_DT cumulative_JJ duration_NN
        of_IN the_DT pulses_NNS and_CC that_IN the_DT necrotic_JJ fibers_NNS never_RB expressed_VBD
        the_DT reporter_NN gene_NN ._. Hartikka_NNP et_CC al_NN ._. attributed_VBD the_DT muscle_NN
        necrosis_NNS to_TO the_DT presence_NN of_IN plasmid_NN ,_, but_CC this_DT conclusion_NN is_VBZ
        difficult_JJ to_TO interpret_VB since_IN the_DT elevation_NN of_IN serum_NN CPK_NNP was_VBD
        not_RB influenced_VBN by_IN the_DT plasmid_NN ._. The_DT lesions_NNS described_VBN by_IN
        these_DT authors_NNS and_CC us_PRP have_VBP much_RB in_IN common_JJ with_IN those_DT induced_VBN
        by_IN electrocution_NN chocks_NNS ._. For_IN instance_NN ,_, Block_NNP et_CC al_NN ._. [_NN 19_CD ]_NN
        ,_, in_IN an_DT attempt_NN to_TO mimic_VB non-thermally_JJ mediated_JJ muscle_NN
        injury_NN in_IN electrical_JJ trauma_NN ,_, used_VBD similar_JJ electric_JJ field_NN
        strength_NN and_CC pulse_NN length_NN as_IN for_IN plasmid_NN electroporation_NN ._.
        This_DT resulted_VBD in_IN quantitatively_RB and_CC qualitatively_RB very_RB
        similar_JJ muscle_NN damage_NN to_TO what_WP we_PRP found_VBD with_IN the_DT
        electroporation_NN procedure_NN ._. Thus_RB ,_, there_EX is_VBZ strong_JJ evidence_NN
        that_DT muscle_NN electroporation_NN ,_, as_IN it_PRP usually_RB performed_VBD ,_, is_VBZ
        severely_RB damaging_JJ and_CC reduces_VBZ plasmid_NN expression_NN to_TO the_DT
        survival_NN cells_NNS ._. Furthermore_RB ,_, even_RB if_IN electrical_JJ injuries_NNS
        generally_RB involve_VBP much_RB higher_JJR field_NN strength_NN [_NN 20_CD ]_NN ,_, it_PRP is_VBZ
        noteworthy_JJ that_IN some_DT pathologic_JJ changes_NNS found_VBD after_IN
        electric_JJ shock_NN resemble_VBP the_DT one_CD observed_VBD in_IN muscle_NN after_IN
        electroporation_NN i_NNP ._. e_SYM ._. the_DT decolouration_NN in_IN bands_NNS of_IN the_DT
        muscle_NN fibbers_NNS described_VBN by_IN Morita_NNP et_CC al_NN ._. [_NN 21_CD ]_NN ._.
        Bureau_NNP et_CC al_NN ._. have_VBP made_VBN attempts_NNS to_TO improve_VB the_DT
        electroporation_NN protocol_NN by_IN introducing_VBG new_JJ settings_NNS ,_,
        consisting_VBG in_IN the_DT combination_NN of_IN high_JJ voltage_NN and_CC low_JJ
        voltages_NNS pulses_NNS ,_, that_WDT are_VBP inducing_VBG less_JJR permeabilisation_NN of_IN
        the_DT myocytes_NNS [_NN 22_CD ]_NN ._. Even_RB if_IN these_DT combined_VBN protocols_NNS
        seems_VBZ to_TO be_VB slightly_RB less_RBR toxic_JJ ,_, there_EX is_VBZ still_RB much_JJ
        improvement_NN needed_VBN to_TO compete_VB with_IN the_DT new_JJ generations_NNS of_IN
        adenoviral_NN vectors_NNS as_IN a_DT method_NN to_TO transfect_NN muscle_NN in_IN
        patients_NNS ._.
        In_IN contrast_NN to_TO intramuscular_NN delivery_NN ,_, the_DT
        electroporation_NN of_IN tumours_NNS seems_VBZ to_TO offer_VB a_DT wider_RBR
        therapeutic_JJ window_NN ._. In_IN case_NN of_IN tumours_NNS that_WDT are_VBP poorly_RB
        permissive_JJ to_TO adenovirus_JJ ,_, it_PRP is_VBZ difficult_JJ to_TO transduce_NN a_DT
        large_JJ number_NN of_IN tumour_NN cells_NNS with_IN adenoviral_NN vectors_NNS
        without_IN inducing_VBG severe_JJ liver_NN damage_NN ._. In_IN contrast_NN ,_, the_DT
        systemic_JJ toxicity_NN is_VBZ not_RB a_DT risk_NN with_IN plasmid_NN
        electroporation_NN as_IN it_PRP is_VBZ with_IN adenoviral_NN transfection_NN ._. The_DT
        possible_JJ damage_NN induced_VBN by_IN the_DT electroporation_NN could_MD not_RB be_VB
        easily_RB determined_VBN due_JJ to_TO the_DT high_JJ background_NN of_IN necrosis_NNS in_IN
        the_DT tumour_NN tissue_NN ,_, but_CC if_IN it_PRP occurs_VBZ it_PRP could_MD only_RB add_VB to_TO
        the_DT therapeutic_JJ effect_NN ._. In_IN our_PRP$ experiments_NNS the_DT
        concentration_NN of_IN plasmid_NN preparations_NNS limited_VBD the_DT maximal_NN
        dose_NN that_WDT could_MD be_VB delivered_VBN into_IN the_DT tumour_NN ,_, but_CC If_IN this_DT
        technical_JJ obstacle_NN of_IN producing_VBG highly_RB concentrated_VBN plasmid_NN
        was_VBD solved_VBN ,_, electroporation_NN would_MD offer_VB an_DT applicable_JJ
        transfection_NN technique_NN for_IN viral-resistant_JJ tumours_NNS that_WDT are_VBP
        accessible_JJ with_IN an_DT electroporation_NN device_NN i_NNP ._. e_SYM ._. head_NN and_CC
        neck_NN or_CC skin_NN cancers_NNS ._.
      
      
        Methods_NNP
        
          Animals_NNS
          Pathogen-free_NNP inbred_JJ male_JJ C_NNP 57_CD Bl_NNP /_NN 6_CD mice_NNS ,_, weighing_VBG 20_CD to_TO
          30_CD gr_NN and_CC Brown_NNP Norway_NNP rats_NNS ,_, weighing_VBG 300_CD to_TO 350_CD gr_NN were_VBD
          purchased_VBN from_IN Harlan_NNP ,_, The_DT Netherlands_NNP ._. All_DT animals_NNS were_VBD
          fed_VBN ad_NN libitum_NN with_IN laboratory_NN chow_NN and_CC water_NN and_CC were_VBD
          kept_VBN under_IN standard_JJ laboratory_NN conditions_NNS ._. For_IN assay_NN of_IN
          plasma_NN creatin_NN phosphokinase_NN (_( CPK_NNP )_) ,_, hEndostatin_NN ,_, and_CC
          mhATF-BPTI_JJ ,_, mice_NNS were_VBD anaesthetised_JJ with_IN isoflurane_NN ,_, bled_VBD
          by_IN tail_NN vein_NN cut_NN and_CC the_DT blood_NN was_VBD collected_VBN in_IN EDTA_NNP
          tubes_NNS ._. All_DT animal_NN procedures_NNS were_VBD performed_VBN in_IN accordance_NN
          with_IN the_DT official_JJ guidelines_NNS after_IN obtaining_VBG permission_NN
          of_IN the_DT animal_NN welfare_NN committee_NN ._. Measurements_NNP of_IN CPK_NNP were_VBD
          performed_VBN according_VBG to_TO standard_JJ clinical_JJ procedures_NNS ._.
        
        
          Plasmid_NNP preparation_NN
          The_DT plasmid_NN pAdapt_NN Luc_NNP ,_, pAdpat_NN LacZ_NNP ,_, pAdapt_NN hEndo_NN and_CC
          pAdapt_NN mhAB_NN encoding_VBG respectively_RB for_IN the_DT luciferase_NN ,_,
          β-galactosidase_JJ ,_, human_JJ endostatine_NN and_CC murinised_JJ human_JJ
          ATF-BPTI_NNP genes_NNS were_VBD constructed_VBN as_IN described_VBN previously_RB [_NN
          23_CD ]_NN ._. The_DT different_JJ genes_NNS are_VBP under_IN the_DT control_NN of_IN the_DT
          cytomegalovirus_JJ (_( CMV_NNP )_) immediate-early_JJ promotor_NN and_CC
          terminated_VBN by_IN the_DT simian_NN virus_NN (_( SV_NNP 40_CD )_) late_JJ poly_RB (_( A_DT )_)
          signal_NN ._. The_DT p_NN Adapt_NNP mhAB_NN encodes_NNS for_IN a_DT murinised_JJ form_NN of_IN
          the_DT human_JJ ATF-BPTI_NNP (_( mhAB_NN )_) [_NN 24_CD ]_NN ._. In_IN this_DT construct_VB the_DT
          mhATF-BPTI_JJ ,_, is_VBZ preceded_VBN by_IN the_DT native_JJ secretion_NN signal_NN
          peptide_NN of_IN the_DT human_JJ urokinase_NN ._. The_DT human_JJ endostatin_NN
          coding_VBG sequence_NN (_( InvivoGen_NNP ,_, CA_NNP ,_, USA_NNP )_) was_VBD cloned_VBN in_IN the_DT Ad_NNP
          Adapt_NNP shuttle_NN vector_NN ._. The_DT encoded_JJ endostatin_NN corresponds_NNS
          to_TO the_DT 183_CD residue_NN of_IN the_DT human_JJ endostatin_NN described_VBN by_IN
          O_NNP '_POS Reilly_NNP et_CC al_NN ._. (_( 1997_CD )_) with_IN an_DT intact_JJ N-_NNP terminus_JJ
          (_( HSHRDFQ_NNP ._. ._. ._. )_) ,_, preceded_VBN by_IN the_DT secretion_NN signal_NN peptide_NN of_IN
          the_DT human_JJ IL-_NNP 2_CD ._. The_DT p_NN Adapt_NNP empty_JJ is_VBZ identical_JJ to_TO p_NN Adapt_NNP
          Luc_NNP except_IN that_IN it_PRP does_VBZ not_RB encode_NN any_DT transgene_NN ._.
          All_DT plasmid_NN DNA_NNP preparations_NNS were_VBD prepared_VBN using_VBG
          Qiagen_NNP Mega_JJ Kits_NNP and_CC purified_JJ using_VBG ENDOfree_NNP kits_NNS
          (_( Qiagen_NNP ,_, Valancia_NNP ,_, CA_NNP )_) ._.
        
        
          Adenoviral_NNP vectors_NNS
          Recombinant_NNP adenovirus_JJ vectors_NNS were_VBD generated_VBN in_IN
          PER_NNP ._. C_NNP 6_CD ™_NN cells_NNS by_IN homologous_RB recombination_NN between_IN an_DT
          adapter_NN plasmid_NN (_( pAdapt_NN )_) and_CC the_DT E_NNP 1_CD deleted_VBN Ad_NN 5_CD DNA_NNP
          plasmid_NN as_IN described_VBN elsewhere_RB [_NN 23_CD ]_NN ._. As_IN a_DT result_NN of_IN
          the_DT absence_NN of_IN sequence_NN overlap_VB between_IN the_DT Adapt_NNP plasmid_NN
          and_CC the_DT Ad_NN 5_CD E_NNP 1_CD sequences_NNS integrated_VBN into_IN the_DT genome_NN of_IN
          PER_NNP ._. C_NNP 6_CD ,_, the_DT vector_NN stocks_NNS used_VBN in_IN this_DT study_NN did_VBD not_RB
          contain_VB replicative_JJ competent_JJ adenovirus_JJ (_( RCA_NNP )_) [_NN 25_CD ]_NN ._.
          All_DT vectors_NNS were_VBD produced_VBN on_IN PER_NNP ._. C_NNP 6_CD ™_NN using_VBG standard_JJ
          procedures_NNS [_NN 25_CD ]_NN ._. Infectious_NNP units_NNS (_( iu_NN )_) /_NN ml_NN were_VBD
          determined_VBN by_IN end_NN point_NN cytopathogenic_JJ effect_NN (_( CPE_NNP )_) assay_NN
          on_IN 911_CD cells_NNS [_NN 26_CD ]_NN ._. Viral_NNP particles_NNS were_VBD determined_VBN by_IN
          HPLC_NNP [_NN 27_CD ]_NN ._. The_DT particle_NN to_TO infectious_JJ unit_NN ratio_NN was_VBD
          always_RB lower_JJR than_IN 5_CD ._.
        
        
          Electric_NNP pulse_NN delivery_NN and_CC intramuscular_NN
          injection_NN
          The_DT animals_NNS were_VBD anaesthetised_JJ by_IN intra_NN peritoneal_JJ
          injection_NN of_IN fentanyl_NN /_NN fluanisone_NN (_( Hypnorm_NNP ,_, Janssen_NNP
          Animal_NNP Health_NNP ,_, The_DT Netherlands_NNP )_) ._. Rear_NNP legs_NNS and_CC the_DT flank_NN
          skin_NN were_VBD shaved_VBN for_IN the_DT muscle_NN and_CC tumoral_NN
          electroporation_NN respectively_RB ._. Fifty_NNP microliter_NN of_IN plasmid_NN
          (_( 50_CD μg_NN )_) or_CC of_IN adenovirus_JJ (_( 10_CD 10_CD iu_NN )_) were_VBD injected_VBN slowly_RB
          to_TO prevent_VB back_RB flow_NN in_IN the_DT gastrocnemius_JJ with_IN a_DT 29_CD Gauge_NNP
          needle_NN ._. When_WRB 2_CD plasmids_NNS were_VBD injected_VBN simultaneously_RB ,_, the_DT
          volume_NN of_IN the_DT mixture_NN was_VBD 100_CD μl_NN ._. The_DT tumours_NNS had_VBD a_DT
          volume_NN of_IN 500_CD cm_NN 3_CD and_CC the_DT injection_NN volume_NN was_VBD 100_CD μl_NN ._.
          Two_CD minutes_NNS after_IN plasmid_NN injection_NN ,_, transcutaneous_JJ
          electric_JJ pulses_NNS were_VBD applied_VBN through_IN two_CD stainless_JJ steel_NN
          plate_NN electrodes_NNS of_IN a_DT dimension_NN of_IN 5_CD ×_NN 10_CD mm_NN (_( BTX_NNP ,_,
          calliper_NN electrodes_NNS ;_: Westburg_NNP ,_, The_DT Netherlands_NNP )_) placed_VBN on_IN
          each_DT side_NN of_IN the_DT leg_NN or_CC the_DT tumour_NN ._. Electrode_NNP jelly_RB was_VBD
          used_VBN on_IN the_DT electrode_NN plates_NNS to_TO ensure_VB good_JJ electrical_JJ
          contact_NN ._. The_DT distance_NN between_IN the_DT electrodes_NNS were_VBD usually_RB
          around_IN 5_CD -_: 6_CD mm_NN ._. The_DT electrodes_NNS were_VBD applied_VBN on_IN the_DT muscle_NN
          until_IN they_PRP came_VBD in_IN complete_JJ contact_NN with_IN the_DT skin_NN ,_, but_CC
          without_IN compressing_VBG the_DT muscle_NN ._. Eight_CD 20_CD -_: ms_NNS pulses_NNS were_VBD
          delivered_VBN at_IN a_DT frequency_NN of_IN 1_CD Hz_NNP using_VBG a_DT BTX_NNP ECM_NNP 830_CD
          electroporator_NN ._. Variation_NNP between_IN 50_CD and_CC 200_CD V_NNP /_NN cm_NN were_VBD
          investigated_VBN in_IN different_JJ experiments_NNS ._.
        
        
          Luciferase_NNP activity_NN assay_NN in_IN tissue_NN
          Mice_NNS were_VBD sacrificed_JJ by_IN an_DT overdose_NN of_IN isoflurane_NN and_CC
          whole_JJ organs_NNS were_VBD dissected_VBN out_IN ,_, frozen_VBN in_IN liquid_JJ
          nitrogen_NN and_CC stored_VBD at_IN -_: 80_CD °_NN C_NNP ._. Organs_NNP were_VBD homogenised_JJ in_IN
          phosphate_NN buffered_JJ saline_NN pH_NN 7_CD ._. 8_CD using_VBG a_DT blender_NN ._. To_TO lyse_NN
          the_DT cells_NNS ,_, DTT_NNP (_( SIGMA_NNP ,_, The_DT Netherlands_NNP )_) (_( 1_CD mM_NN )_) and_CC Triton_NNP
          x-_NN 100_CD (_( 0_CD ._. 1_LS %_NN )_) (_( Merck_NNP ,_, The_DT Netherlands_NNP )_) were_VBD added_VBN ._. After_IN
          centrifugation_NN at_IN 10_CD ,_, 000_CD rpm_NN for_IN 10_CD min_NN ,_, 20_CD μl_NN of_IN the_DT
          supernatant_NN was_VBD added_VBN to_TO 100_CD μl_NN of_IN luciferase_NN assay_NN
          substrate_NN (_( Promega_NNP ,_, The_DT Netherlands_NNP )_) ._. Relative_NNP light_JJ
          units_NNS (_( RLU_NNP )_) were_VBD determined_VBN for_IN 30_CD s_VBZ using_VBG a_DT luminometer_NN
          (_( Lumat_NNP 951_CD ,_, Wallac_NNP ,_, Belgium_NNP )_) ._. The_DT amount_NN of_IN protein_NN in_IN
          the_DT extracts_NNS was_VBD determined_VBN with_IN a_DT commercial_JJ kit_NN
          (_( Bio-_NNP Rad_NNP laboratories_NNS ,_, The_DT Netherlands_NNP )_) based_VBN on_IN the_DT
          Coomasie_NNP brilliant_JJ blue_JJ G_NNP 250_CD binding_JJ assay_NN [_NN 28_CD ]_NN ._. The_DT
          level_NN of_IN luciferase_NN activity_NN in_IN the_DT tissue_NN homogenates_NNS
          was_VBD expressed_VBN in_IN RLU_NNP /_NN mg_NN protein_NN ._.
        
        
          Elisa_NNP assays_NNS
          The_DT mhATF-BPTI_JJ ELISA_NNP was_VBD developed_VBN by_IN P_NN ._. Quax_NNP et_CC al_NN ._.
          (_( TNO-Prevention_NNP and_CC Health_NNP ,_, Leiden_NNP The_DT Netherlands_NNP )_) ,_,
          using_VBG a_DT monoclonal_NN antibody_NN specific_JJ for_IN the_DT ATF_NNP as_IN the_DT
          capture_NN antibody_NN and_CC a_DT polyclonal_NN antibody_NN directed_VBN
          against_IN BPTI_NNP as_IN the_DT detector_NN antibody_NN [_NN 24_CD ]_NN ._. As_IN a_DT
          standard_JJ we_PRP used_VBD either_CC urokinase_NN or_CC mhATF-BPTI_JJ ._. The_DT
          levels_NNS of_IN human_JJ endostatin_NN in_IN mice_NNS plasma_NN were_VBD determined_VBN
          with_IN an_DT ELISA_NNP kit_NN (_( InvivoGen_NNP ,_, CA_NNP USA_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN procedure_NN ._.
        
        
          Cell_NNP line_NN
          The_DT L_NNP 44_CD adenocarcinoma_NN was_VBD induced_VBN in_IN Brown_NNP Norway_NNP
          rats_NNS by_IN local_JJ irradiation_NN of_IN the_DT thorax_NN [_NN 29_CD ]_NN ._. The_DT L_NNP 44_CD
          carcinoma_NN was_VBD serially_RB passaged_JJ on_IN syngeneic_JJ rats_NNS ._. For_IN
          the_DT experiments_NNS ,_, the_DT tumours_NNS were_VBD established_VBN in_IN the_DT
          flank_NN of_IN rats_NNS by_IN implanting_VBG small_JJ pieces_NNS (_( 3_CD ×_NN 3_CD ×_NN 3_CD mm_NN )_)
          of_IN tumour_NN tissue_NN sub-cutaneously_JJ as_IN described_VBN before_IN [_NN 30_CD
          ]_NN ._.
        
        
          LacZ_NNP expression_NN assay_NN
          Forty-eight_NNP hours_NNS after_IN Ad_NN 5_CD Adapt_NNP LacZ_NNP administration_NN
          rats_NNS were_VBD sacrificed_JJ and_CC tumours_NNS were_VBD removed_VBN and_CC cut_VB in_IN
          2_CD mm_NN sections_NNS ._. Sections_NNP were_VBD fixed_VBN in_IN 10_CD %_NN phosphate_NN
          buffered_JJ formalin_NN (_( pH_NN 7_CD ._. 0_CD )_) for_IN 60_CD min_NN at_IN room_NN temperature_NN
          and_CC incubated_JJ overnight_JJ in_IN 0_CD ._. 5_CD M_NNP sucrose_NN ._. The_DT samples_NNS
          were_VBD subsequently_RB frozen_VBN in_IN liquid_JJ nitrogen_NN ._. Ten_CD μm_NN thick_JJ
          frozen_VBN sections_NNS were_VBD prepared_VBN and_CC stained_JJ with_IN
          5_CD -_: bromo-_NN 4_CD -_: chloro-_NN 3_CD -_: indolyl-β-galactopyranoside_JJ (_( X-_NNP gal_NN )_)
          solution_NN (_( Molecular_NNP Probes_NNP ,_, The_DT Netherlands_NNP )_) overnight_JJ at_IN
          37_CD °_NN C_NNP ._. Finally_RB ,_, sections_NNS were_VBD counterstained_JJ with_IN
          haematoxylin_NN and_CC eosin_NN ._. The_DT percentage_NN of_IN transduced_JJ
          cells_NNS in_IN an_DT histological_JJ section_NN was_VBD assessed_VBN by_IN the_DT
          surface_NN of_IN stained_JJ cells_NNS divided_VBN by_IN the_DT whole_JJ section_NN
          surface_NN ._. Cells_NNP were_VBD considered_VBN positive_JJ when_WRB a_DT blue_JJ
          staining_VBG was_VBD seen_VBN in_IN the_DT nucleus_NN ._. The_DT surface_NN of_IN stained_JJ
          cells_NNS in_IN each_DT section_NN was_VBD determined_VBN on_IN digitalised_JJ
          photographs_NNS of_IN 25_CD ×_NN magnification_NN fields_NNS ._. The_DT surface_NN
          measurements_NNS were_VBD performed_VBN with_IN the_DT NIH_NNP Image_NN 1_CD ._. 62_CD
          software_NN ._.
        
        
          Pathology_NNP
          The_DT microscopic_JJ examination_NN of_IN the_DT gastrocnemius_JJ was_VBD
          performed_VBN on_IN paraffin_NN section_NN of_IN formalin-fixated_JJ muscle_NN ._.
          Ten_CD transversal_NN sections_NNS form_VBP one_CD extremity_NN to_TO the_DT other_JJ
          were_VBD performed_VBN and_CC stained_JJ with_IN haematoxylin_NN and_CC eosin_NN ._.
          All_DT sections_NNS were_VBD examined_VBN but_CC the_DT quantification_NN of_IN the_DT
          rhabdomyolysis_NNS was_VBD determined_VBN on_IN 3_CD sections_NNS ,_, 1_CD mm_NN apart_RB
          from_IN each_DT other_JJ ,_, cut_VB through_IN the_DT part_NN of_IN the_DT muscle_NN that_WDT
          was_VBD electroporated_JJ ._. The_DT percentage_NN of_IN necrotic_JJ fibers_NNS was_VBD
          quantified_VBN on_IN photographs_NNS of_IN 25_CD ×_NN magnification_NN field_NN ._.
          The_DT surface_NN of_IN the_DT necrotic_JJ areas_NNS was_VBD measured_VBN with_IN the_DT
          NHI_NNP image_NN analyser_NN software_NN and_CC reported_VBD to_TO the_DT total_JJ
          surface_NN of_IN the_DT whole_JJ sections_NNS ._.
          The_DT scoring_VBG of_IN the_DT liver_NN damage_NN was_VBD performed_VBN in_IN Brown_NNP
          Norway_NNP rats_NNS 7_CD days_NNS after_IN the_DT intravenous_JJ injection_NN of_IN 10_CD
          10_CD iu_NN Ad_NNP Adapt_NNP Empty_JJ ._. The_DT liver_NN pieces_NNS were_VBD fixed_VBN in_IN
          formalin_NN 10_CD %_NN ,_, embedded_VBN in_IN paraffin_NN and_CC sections_NNS of_IN 10_CD μm_NN
          were_VBD stained_JJ with_IN haematoxylin_NN and_CC eosin_NN ._. The_DT total_JJ
          damage_NN score_NN is_VBZ a_DT compilation_NN of_IN scores_NNS of_IN apoptosis_NNS ,_,
          vacuolar_NN changes_NNS ,_, nuclear_JJ condensation_NN ,_, anisonucleosis_NNS ,_,
          megalocytosis_NNS ,_, mitosis_NNS ,_, and_CC inflammation_NN ._. Normal_NNP control_NN
          liver_NN score_NN is_VBZ zero_CD and_CC the_DT maximal_NN is_VBZ nine_CD ._.
        
      
      
        List_NN of_IN abbreviations_NNS
        ATF_NNP :_: Amino_NNP Terminal_NNP Fragment_NNP
        BPTI_NNP :_: Bovine_NNP Pancreatic_NNP Trypsine_NNP Inhibitor_NNP
        ELISA_NNP :_: human_JJ enzyme-linked_JJ immunoabsorbent_NN assay_NN
        iu_NN :_: Infectious_NNP units_NNS
        iv_NN :_: Intra_NNP venous_JJ
        mhATF-BPTI_JJ :_: murinised_JJ human_JJ ATF-BPTI_NNP
        vp_NN :_: virus_NN particle_NN
      
    
  
